Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 DiabetesBusiness Wire • 11/17/20
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt FundBusiness Wire • 11/12/20
These Red-Hot Biotechs Are Leading The Pack And Could Be ActionableInvestors Business Daily • 11/10/20
Bayer Submits Regulatory Applications for Investigational Drug Finerenone in the U.S. and the EU for Patients with Chronic Kidney Disease and Type 2 DiabetesBusiness Wire • 11/09/20
Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/03/20
Bayer Aktiengesellschaft's (BAYZF) CEO Werner Baumann On Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/03/20
Bayer Signs Letter of Intent to Build New Distribution Center in Saxonburg, PABusiness Wire • 10/27/20
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene TherapyBusiness Wire • 10/26/20
Bayer's FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 DiabetesBusiness Wire • 10/23/20